One hundred and sixty-one female patients, over the age of 70, with breast cancer were treated by Tamoxifen alone in a pilot phase II study. 61% showed objective regression of the disease and in 27% there was complete remission. The treatment was well tolerated and the survival rate compared favourably to that following conventional methods of treatment. An accurate assessment of the method awaits a randomized clinical trial.